Original articleCardiovascularImproved Mechanical Reliability of the HeartMate XVE Left Ventricular Assist System
Section snippets
Device
Incremental improvements were made to the current HeartMate XVE device in comparison with the previous HeartMate VE model. The first significant change was to the inflow valve assembly with the addition of sutures at the valve commissures to strengthen the attachment to the graft material, prevent valve dysfunction, and reduce the risk of disconnection (Fig 1). High pressure in the pump chamber would tend to displace the original valve and cause graft distortion. In addition, sutures that
Results
From September 28, 1998, through May 31, 2004, 147 patients underwent implantation of 167 HeartMate VE devices and 98 patients underwent implantation of 101 HeartMate XVE devices. There were no significant differences between groups with regard to age, sex, cause of the heart failure, percent of patients undergoing implantation for bridge to transplant indication, and volume of implants at each participating center (Table 1). The median duration of support for the VE was 159 days (range, 0 to
Comment
Data from this study demonstrate that important design modifications to the HeartMate XVE LVAD have resulted in a significantly decreased incidence of major device malfunctions. Importantly, significantly fewer major device malfunctions occurred with similar duration of device support between the groups. This decrease in incidence of major device malfunctions was primarily attributable to the significant reduction in incidence of both inflow valve dysfunction and bearing wear (either main
References (14)
- et al.
The registry of the International Society for Heart and Lung Transplantation; seventeenth official report—2000
J Heart Lung Transplant
(2000) - et al.
Significant reduction in major LVAD device failures: comparison of the HeartMate® VE and XVE LVAS
J Heart Lung Transplant
(2003) - et al.
Left ventricular assist devices as destination therapy: a new look at survival
J Thorac Cardiovasc Surg
(2005) Advanced mechanical circulatory support with the HeartMate left ventricular assist device in the year 2000
Ann Thorac Surg
(2001)Worldwide experience with the TCI HeartMate system: issues and future perspective
Thorac Cardiovasc Surg
(1999)- et al.
Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system
Ann Surg
(1995) Heart Disease and Stroke Statistics—2004 update
(2003)
Cited by (49)
Intraoperative and Early Postoperative Management of Patients Undergoing Minimally Invasive Left Ventricular Assist Device Implantation
2021, Journal of Cardiothoracic and Vascular AnesthesiaDuration of Left Ventricular Assist Device Support Does Not Impact Survival After US Heart Transplantation
2016, Annals of Thoracic SurgeryPhysiologic effects of continuous-flow left ventricular assist devices
2016, Journal of Surgical ResearchCitation Excerpt :Despite the dramatically improved survival offered by the use of these pulsatile-flow devices, there were several disadvantages associated with their use. First, the use of various bearings and valves used in pulsatile designs was associated with limited durability, requiring many patients to undergo LVAD replacement surgery [7–9]. Second, pulsatile LVADs used the use of a volume displacement chamber, resulting in a relatively large device.
Left ventricular assist devices: The adolescence of a disruptive technology
2015, Journal of Cardiac FailureCitation Excerpt :The first device approved for DT was the Heartmate XVE (Thoratec), a volume-displacement pump comprising a blood-contacting pusher-plate, a rotating motor, and 2 valves that ensured unidirectional blood flow. This pump's failure rates increased substantially at ∼18 months, often owing to incompetency of the inflow valve.4 This failure contributed to the relatively low 2-year survival rate of 23% seen in the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial and to delayed acceptance of DT as viable therapy for patients with advanced heart failure.5,6
Adjunctive Therapies with LVADs: Combining Biological and Mechanical Regenerative Therapies
2015, Stem Cell and Gene Therapy for Cardiovascular DiseaseDurability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011
2013, Journal of Thoracic and Cardiovascular SurgeryCitation Excerpt :In the present trial, cerebrovascular accidents (10/37 patients), infection (7/37 patients), and cardiac dysfunction (5/37 patients) were the most commonly reported causes of death. The results of clinical trials stimulated design changes in pulsatile pumps that resulted in improved patient outcomes, defined as improved survival with fewer adverse events.11,12 However, the disadvantages of pulsatile implantable blood pumps compared with implanted rotary CF pumps (eg, patient acceptance, ease of implantation) resulted in dominance of the field by CF designs.